|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 |
| (11) | Patento numeris | 3057616 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14854535.3 |
| Europos patento paraiškos padavimo data | 2014-10-16 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-08-24 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-03-11 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2014/060810 |
| Data | 2014-10-16 |
| (87) | Numeris | WO 2015/057910 |
| Data | 2015-04-23 |
| (30) | Numeris | Data | Šalis |
| 201361891485 P | 2013-10-16 | US |
| (72) |
CINI, John, US
NAGI, Athena, US
TADDEI, Maria, US
|
| (73) |
Outlook Therapeutics, Inc.,
7 Clarke Drive, Cranbury, NJ 08512,
US
|
| (54) | BUFFER FORMULATIONS FOR ENHANCED ANTIBODY STABILITY |
| BUFFER FORMULATIONS FOR ENHANCED ANTIBODY STABILITY |